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the aspirin and statin components of the polypill.
Third, approximately 50% of the study population had a pre-existing diagnosis of hypertension. Despite that, the reported mean systolic blood pressure was 128-134 mm Hg for both groups and was well controlled to begin with. Adding low-dose enalapril and hydrochlorothiazide would be unlikely to reduce adverse cardiovascular outcomes at followup (no significant difference in blood pressure was shown between the treatment and placebo groups), which supports the notion that the main effect was probably due to statin and aspirin.
Finally, the adherence of participants to lifestyle interventions was not reported or measured in either the intervention group or the placebo group, which could have affected the results if there were significant differences between them. In view of these issues, and the evidence from the aspirin primary prevention trials, the use of the polypill strategy, which seems promising and easily applicable, still requires more data before recommending it for the general population. Targeting specific risk factors and tailoring therapy according to precise risk estimates in individual patients seems more judicious in this era of precision medicine.
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Second, more than 50% of the study participants had total cholesterol of more than 198 mg/dL and mean LDL cholesterol of 117 mg/dL. 1 The adjusted hazard ratio (HR) for major cardiovascular events in the polypill group was 0·66 (95% CI 0·55-0·80). 1 In the JUPITER trial, 4 participants had a mean LDL cholesterol of less than 130 mg/dL and the HR for major cardiovascular events was 0·48 (0·33-0·68) in the rosuvastatin group compared with the placebo group. Moreover, the meta-analysis by Zheng and Roddick 5 showed an HR of 0·89 (0·84-0·95) for major cardiovascular events with aspirin use in primary prevention. Hence, the effects on these events, including cardiovascular mortality, seem to be mostly (if not completely) related to
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